The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

Nature Reviews Immunology

Volumn 15, Issue 5, 2015, Pages 283-294

  Klatzmann, David ^a,b,c   Abbas, Abul K ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b Sorbonne Université   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; ANTIVIRUS AGENT; CD19 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE PIM 1; RITUXIMAB; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL STATUS; GENE ACTIVATION; GRAFT VERSUS HOST REACTION; HEPATITIS C; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THERAPY EFFECT; VASCULITIS; VIRUS LOAD; AUTOIMMUNE DISEASES; IMMUNOLOGY;

ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 84928591321     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3823     Document Type: Review

References (122)

1. Sakaguchi, S., Powrie, F. & Ransohoff, R. M. Re-establishing immunological self-tolerance in autoimmune disease. Nature Med. 18, 54-58 (2012).
2. Shevach, E. M. & Thornton, A. M. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev. 259, 88-102 (2014).
3. Moraes-Vasconcelos, D., Costa-Carvalho, B. T., Torgerson, T. R. & Ochs, H. D. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J. Clin. Immunol. 28 (Suppl. 1), 11-19 (2008).
4. Godfrey, V., Wilkinson, J. & Russell, L. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 138, 1379-1387 (1991).
5. Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 13, 668-677 (2014).
6. Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nature Immunol. 8, 191-197 (2007).
7. Marek-Trzonkowska, N. et al. Administration of CD4+CD25highCD127-regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 35, 1817-1820 (2012).
8. Malek, T. R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453-479 (2008).
9. Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nature Rev. Immunol. 12, 180-190 (2012).
10. Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13-25 (2013).
11. Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067-2077 (2011).
12. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066 (2011).
13. Robb, R. J. Interleukin 2: the molecule and its function. Immunol. Today 5, 203-209 (1984).
14. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
15. Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268, 1472-1476 (1995).
16. Willerford, D. M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
17. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
18. Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167-178 (2002).
19. Vang, K. B. et al. IL-2,-7, and-15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J. Immunol. 181, 3285-3290 (2008).
20. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunol. 6, 1142-1151 (2005).
21. Barron, L. et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J. Immunol. 185, 6426-6430 (2010).
22. Feng, Y. et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 158, 749-763 (2014).
23. Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785-799 (2012).
24. Williams, M. A., Tyznik, A. J. & Bevan, M. J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441, 890-893 (2006).
25. Kalia, V. et al. Prolonged interleukin-2Rα expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32, 91-103 (2010).
26. Pipkin, M. E. et al. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32, 79-90 (2010).
27. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
28. Bilate, A. M. & Lafaille, J. J. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30, 733-758 (2012).
29. Cote-Sierra, J. et al. Interleukin 2 plays a central role in TH2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880-3885 (2004).
30. Liao, W. et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc. Natl Acad. Sci. USA 111, 3508-3513 (2014).
31. Liao, W., Lin, J.-X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nature Immunol. 12, 551-559 (2011).
32. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371-381 (2007).
33. Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847-856 (2012).
34. Linterman, M. A. et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nature Med. 17, 975-982 (2011).
35. Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nature Med. 17, 983-988 (2011).
36. Wollenberg, I. et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J. Immunol. 187, 4553-4560 (2011).
37. Neill, D. R. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370 (2010).
38. Roediger, B. et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nature Immunol. 14, 564-573 (2013).
39. Van Gool, F. et al. Interleukin-5 producing group 2 innate lymphoid cells (ILC2) control eosinophilia induced by interleukin-2 therapy. Blood 124, 3572-3576 (2014).
40. Ribot, J. C., Ribeiro, S. T., Correia, D. V., Sousa, A. E. & Silva-Santos, B. Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling. J. Immunol. 192, 2237-2243 (2014).
41. Yu, A, Zhu, L., Altman, N. H. & Malek, T. R. A low interleukin- 2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204-217 (2009).
42. Yu, A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms support the use of low-dose IL-2 therapy in type-1 diabetes. Diabetes http://dx.doi.org/10.2337/db14-1322 (2015).
43. Bensinger, S. J. et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J. Immunol. 172, 5287-5296 (2004).
44. Walsh, P. T. et al. PTEN inhibits IL-2 receptormediated expansion of CD4+ CD25+ Tregs. J. Clin. Invest. 116, 2521-2531 (2006).
45. Contractor, N. V. et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J. Immunol. 160, 385-394 (1998).
46. Schultz, M. et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am. J. Physiol. 276, G1461-G1472 (1999).
47. Sharfe, N., Dadi, H. K., Shahar, M. & Roifman, C. M. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94, 3168-3171 (1997).
48. Smigiel, K. S. et al. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J. Exp. Med. 211, 121-136 (2014).
49. Gratz, I. K. et al. Cutting edge: memory regulatory T cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J. Immunol. 190, 4483-4487 (2013).
50. Raynor, J. et al. IL-15 fosters age-driven regulatory T cell accrual in the face of declining IL-2 levels. T Cell Biol. 4, 161 (2013).
51. Zier, K. S., Leo, M. M., Spielman, R. S. & Baker, L. Decreased synthesis of interleukin-2 (IL-2) in insulindependent diabetes mellitus. Diabetes 33, 552-555 (1984).
52. Kitas, G. D., Salmon, M., Farr, M., Gaston, J. S. & Bacon, P. A. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. Clin. Exp. Immunol. 73, 242-249 (1988).
53. Lieberman, L. A. & Tsokos, G. C. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. Biomed. Biotechnol. 2010, 740619 (2010).
54. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
55. Rouse, M., Nagarkatti, M. & Nagarkatti, P. S. The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis. Immunobiology 218, 674-682 (2013).
56. Hao, J. et al. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 69, 721-734 (2011).
57. Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871-1878 (2010).
58. Mizui, M. et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8-IL-17-producing T cells. J. Immunol. 193, 2168-2177 (2014).
59. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
60. Liu, R. et al. Expansion of regulatory T cells via IL-2/ anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 40, 1577-1589 (2010).
61. Ait-Oufella, H. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nature Med. 12, 178-180 (2006).
62. Mack, D. G. et al. Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease. Proc. Natl Acad. Sci. USA 111, 8553-8558 (2014).
63. Villalta, S. A. et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 6, 258ra142 (2014).
64. Taniguchi, T. et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305-310 (1983).
65. Bindon, C. et al. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br. J. Cancer 47, 123-133 (1983).
66. Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J. & Rosenberg, S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134, 157-166 (1985).
67. Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
68. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
69. Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
70. Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451-5458 (2014).
71. Ahmadzadeh, M. & Rosenberg, S. A. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409-2414 (2006).
72. Zhang, H. et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nature Med. 11, 1238-1243 (2005).
73. Lemoine, F. M. et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a Phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int. J. Oncol. 35, 569-581 (2009).
74. Weiss, L. et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc. Natl Acad. Sci. USA 107, 10632-10637 (2010).
75. Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906-11911 (2010).
76. London, N. R. et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci. Transl. Med. 2, 23ra19 (2010).
77. Ferrara, J. L. Cytokine dysregulation as a mechanism of graft versus host disease. Curr. Opin. Immunol. 5, 794-799 (1993).
78. Boyer, O. et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 103, 3428-3430 (2004).
79. Saadoun, D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111, 5334-5341 (2008).
80. Landau, D.-A. et al. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum. 58, 2897-2907 (2008).
81. Alric, L. et al. Pilot study of interferon-α-ribavirininterleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. J. Viral Hepat. 13, 139-144 (2006).
82. Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a Phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295-305 (2013).
83. Castela, E. et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 150, 748-751 (2014).
84. Kennedy-Nasser, A. A. et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin. Cancer Res. 20, 2215-2225 (2014).
85. Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory-tuned milieu in T1D patients. J. Autoimmun. 58, 48-58 (2015).
86. Ito, S. et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol. Ther. J. Am. Soc. Gene Ther. 22, 1388-1395 (2014).
87. Matsuoka, K. et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 5, 179ra43 (2013).
88. Aoyama, A. et al. Low-dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates. Am. J. Transpl. 12, 2532-2537 (2012).
89. Chaput, N. et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58, 520-529 (2009).
90. Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791-792 (2015).
91. Gutierrez-Ramos, J. C., Andreu, J. L., Revilla, Y., Vinuela, E. & Martinez, C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346, 271-274 (1990).
92. Goudy, K. S. et al. Inducible adeno-associated virusmediated IL-2 gene therapy prevents autoimmune diabetes. J. Immunol. 186, 3779-3786 (2011).
93. Churlaud, G. et al. Sustained stimulation and expansion of Tregs by IL-2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin. Immunol. 151, 114-126 (2014).
94. Yamaguchi, T., Wing, J. B. & Sakaguchi, S. Two modes of immune suppression by Foxp3+ regulatory T cells under inflammatory or non-inflammatory conditions. Semin. Immunol. 23, 424-430 (2011).
95. Billiard, F. et al. Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J. Immunol. 177, 2167-2174 (2006).
96. Sakaguchi, S., Vignali, D. A. A., Rudensky, A. Y., Niec, R. E. & Waldmann, H. The plasticity and stability of regulatory T cells. Nature Rev. Immunol. 13, 461-467 (2013).
97. Van Loosdregt, J. et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259-271 (2013).
98. Chen, Z. et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39, 272-285 (2013).
99. Li, Z. et al. PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J. Biol. Chem. 289, 26872-26881 (2014).
100. Li, C. et al. MeCP2 enforces Foxp3 expression to promote regulatory T cells' resilience to inflammation. Proc. Natl Acad. Sci. USA 111, E2807-E2816 (2014).
101. Dietrich, T. et al. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis 220, 329-336 (2012).
102. Dinh, T. N. et al. Cytokine therapy with interleukin-2/ anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 126, 1256-1266 (2012).
103. D'Alessio, F. R. et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J. Clin. Invest. 119, 2898-2913 (2009).
104. Wilson, M. S. et al. Suppression of murine allergic airway disease by IL-2: anti-IL-2 monoclonal antibody-induced regulatory T cells. J. Immunol. 181, 6942-6954 (2008).
105. Rosenberg, H. F., Dyer, K. D. & Foster, P. S. Eosinophils: changing perspectives in health and disease. Nature Rev. Immunol. 13, 9-22 (2013).
106. Oliphant, C. J. et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4+ T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41, 283-295 (2014).
107. Zheng, X. X. et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19, 503-514 (2003).
108. Blackman, M. A. & Woodland, D. L. The narrowing of the CD8 T cell repertoire in old age. Curr. Opin. Immunol. 23, 537-542 (2011).
109. Thomas-Vaslin, V. et al. in Immunosuppression-Role in Health and Diseases. (eds Kapur, S. & Portela, M. B.) 125-147 (Intech, 2012).
110. Harvill, E. T. & Morrison, S. L. An IgG3-IL2 fusion protein activates complement, binds Fcγ RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnol. Int. J. Immunol. Eng. 1, 95-105 (1995).
111. Shanafelt, A. B. et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nature Biotech. 18, 1197-1202 (2000).
112. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533 (2012).
113. Rosalia, R. A., Arenas-Ramirez, N., Bouchaud, G., Raeber, M. E. & Boyman, O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr. Opin. Chem. Biol. 23, 39-46 (2014).
114. Kaufman, H. L. et al. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Rev. Clin. Oncol. 10, 588-598 (2013).
115. Kasakura, S. & Lowenstein, L. A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. Nature 208, 794-795 (1965).
116. Gordon, J. & MacLean, L. D. A lymphocyte-stimulating factor produced in vitro. Nature 208, 795-796 (1965).
117. Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007-1008 (1976).
118. Gillis, S., Baker, P. E., Ruscetti, F. W. & Smith, K. A. Long-term culture of human antigen-specific cytotoxic T-cell lines. J. Exp. Med. 148, 1093-1098 (1978).
119. Smith, K. A. Interleukin-2: inception, impact, and implications. Science 240, 1169-1176 (1988).
120. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
121. Prometheus Laboratories. Proleukin® (aldesleukin). [online], http://www.proleukin.com/assets/proleukin. pdf (2012).
122. Churlaud, G. et al. Human and mouse CD8+CD25+FOXP3+ regulatory T cells at steady state and during interleukin-2 therapy. Front. Immunol. http://dx.doi.org/10.3389/fimmu.2015.00171 (2015).